June 28, 2022
Novo Nordisk Pharma on June 27 submitted an application in Japan seeking a label expansion of its long-acting human growth hormone Sogroya Subcutaneous Injection (somapacitan) for the treatment of short stature due to growth hormone deficiency without epiphyseal closure, it...read more